CARB-X to fund development of E coli vaccine
Portuguese biotechnology company Immunethep is receiving $2 million from CARB-X to develop a conjugate peptide-based vaccine against E coli.
www.cidrap.umn.edu/a...
Portuguese biotechnology company Immunethep is receiving $2 million from CARB-X to develop a conjugate peptide-based vaccine against E coli.
www.cidrap.umn.edu/a...
CARB-X to fund development of E coli vaccine
Portuguese biotechnology company Immunethep is receiving $2 million from CARB-X to develop a conjugate peptide-based vaccine against E coli.
www.cidrap.umn.edu
February 25, 2025 at 9:31 PM
CARB-X to fund development of E coli vaccine
Portuguese biotechnology company Immunethep is receiving $2 million from CARB-X to develop a conjugate peptide-based vaccine against E coli.
www.cidrap.umn.edu/a...
Portuguese biotechnology company Immunethep is receiving $2 million from CARB-X to develop a conjugate peptide-based vaccine against E coli.
www.cidrap.umn.edu/a...
A conjugate molecule activates a whopping five receptors on the cell surface and in the nucleus—and in mice, it appears to offer a potent, safe treatment for obesity and diabetes.
#chemsky 🧪
#chemsky 🧪
Not just GLP-1: Peptide-drug conjugate hits 5 obesity targets
Researchers combine pan-PPAR and dual-incretin receptor agonists for dramatic weight loss in mice
cen.acs.org
May 1, 2026 at 9:47 PM
A conjugate molecule activates a whopping five receptors on the cell surface and in the nucleus—and in mice, it appears to offer a potent, safe treatment for obesity and diabetes.
#chemsky 🧪
#chemsky 🧪
There’s no treatment for rabies, which is nearly 100% fatal after symptoms begin. But a triple-antibody cocktail conjugated to a peptide that increases blood–brain barrier penetration resulted in 80% survival in rabid mice in tests. In PNAS: https://ow.ly/4eAF50XRabv
January 2, 2026 at 11:00 PM
There’s no treatment for rabies, which is nearly 100% fatal after symptoms begin. But a triple-antibody cocktail conjugated to a peptide that increases blood–brain barrier penetration resulted in 80% survival in rabid mice in tests. In PNAS: https://ow.ly/4eAF50XRabv
Congratulations to the team at TwoStep Tx, led by former @stanford.edu PhD student-turned-CEO Caitlyn Miller
endpoints.news/cancer-biote...
endpoints.news/cancer-biote...
Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic
TwoStep raised a $62.5M Series A backed by Pfizer and Merck KGaA's venture arms to push its peptide-drug conjugate toward Phase 1 this year.
endpoints.news
September 9, 2026 at 8:20 PM
Congratulations to the team at TwoStep Tx, led by former @stanford.edu PhD student-turned-CEO Caitlyn Miller
endpoints.news/cancer-biote...
endpoints.news/cancer-biote...
An inflammation-responsive, self-immolative prodrug conjugate strategy is developed for oral delivery of peptide therapeutics
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
January 14, 2026 at 7:18 PM
An inflammation-responsive, self-immolative prodrug conjugate strategy is developed for oral delivery of peptide therapeutics
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
I'm a big fan of this database of peptide-drug conjugates. It's a miracle they were able to consolidate chemical rep. and experiments for PDCs across stages (the majority are not on ChEMBL); but they're still missing monomer descriptions of PDCs (i.e. HELM representation)... doi.org/10.1093/nar/...
PDCdb: the biological activity and pharmaceutical information of peptide–drug conjugate (PDC)
Abstract. Peptide–drug conjugates (PDCs) have emerged as a promising class of targeted therapeutics with substantial pharmaceutical advantages and market p
doi.org
December 16, 2024 at 4:34 PM
I'm a big fan of this database of peptide-drug conjugates. It's a miracle they were able to consolidate chemical rep. and experiments for PDCs across stages (the majority are not on ChEMBL); but they're still missing monomer descriptions of PDCs (i.e. HELM representation)... doi.org/10.1093/nar/...
Thoughts on this? >> Avacta expands peptide-drug conjugate study after seeing 10%
response rate: Avacta is stepping up development of its peptide-drug conjugate,… >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #competitivemarketing #pharma #healthcare
response rate: Avacta is stepping up development of its peptide-drug conjugate,… >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #competitivemarketing #pharma #healthcare
Avacta expands peptide-drug conjugate study after seeing 10%
response rate
Avacta is stepping up development of its peptide-drug conjugate, kicking off expansion cohorts in multiple tumor types after seeing one partial response in 10 salivary gland cancer patients.
dlvr.it
January 16, 2025 at 3:01 PM
Thoughts on this? >> Avacta expands peptide-drug conjugate study after seeing 10%
response rate: Avacta is stepping up development of its peptide-drug conjugate,… >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #competitivemarketing #pharma #healthcare
response rate: Avacta is stepping up development of its peptide-drug conjugate,… >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #competitivemarketing #pharma #healthcare
Systemic study on anti-tumor activity of HER2 induced peptide-drug conjugate clustering in xenograft tumor models
doi.org/10.1016/j.cc...
doi.org/10.1016/j.cc...
April 28, 2025 at 1:21 AM
Systemic study on anti-tumor activity of HER2 induced peptide-drug conjugate clustering in xenograft tumor models
doi.org/10.1016/j.cc...
doi.org/10.1016/j.cc...
Targeting Breast cancer cell-derived Fibulin-4/FBLN4 to suppress Lung Metastasis
BLMP6, a cyclic CRAGVGRGC peptide, structurally similar to LTBP4, ⏬FBLN4-LTBP4 interaction
Monomethyl auristatin E-BLMP6 conjugate⏬B16F10 or MDA-MB-231 🫁metastasis in🐭
bioRxiv 2025
www.biorxiv.org/content/10.1...
BLMP6, a cyclic CRAGVGRGC peptide, structurally similar to LTBP4, ⏬FBLN4-LTBP4 interaction
Monomethyl auristatin E-BLMP6 conjugate⏬B16F10 or MDA-MB-231 🫁metastasis in🐭
bioRxiv 2025
www.biorxiv.org/content/10.1...
July 19, 2025 at 11:52 AM
Targeting Breast cancer cell-derived Fibulin-4/FBLN4 to suppress Lung Metastasis
BLMP6, a cyclic CRAGVGRGC peptide, structurally similar to LTBP4, ⏬FBLN4-LTBP4 interaction
Monomethyl auristatin E-BLMP6 conjugate⏬B16F10 or MDA-MB-231 🫁metastasis in🐭
bioRxiv 2025
www.biorxiv.org/content/10.1...
BLMP6, a cyclic CRAGVGRGC peptide, structurally similar to LTBP4, ⏬FBLN4-LTBP4 interaction
Monomethyl auristatin E-BLMP6 conjugate⏬B16F10 or MDA-MB-231 🫁metastasis in🐭
bioRxiv 2025
www.biorxiv.org/content/10.1...
Systemic study on anti-tumor activity of HER2 induced peptide-drug conjugate clustering in xenograft tumor models
Systemic study on anti-tumor activity of HER2 induced peptide-drug conjugate clustering in xenograft tumor models
doi.org/10.1016/j.cc...
doi.org/10.1016/j.cc...
April 28, 2025 at 6:31 AM
Systemic study on anti-tumor activity of HER2 induced peptide-drug conjugate clustering in xenograft tumor models
Now Amgen trying to elbow in the space occupied by Eli Lilly and Novo Nordisk!
www.nejm.org/doi/full/10....
@rnflex.bsky.social
www.nejm.org/doi/full/10....
@rnflex.bsky.social
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial | NEJM
Maridebart cafraglutide (known as MariTide) is a long-acting peptide–antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide recep...
www.nejm.org
June 25, 2025 at 3:00 AM
Now Amgen trying to elbow in the space occupied by Eli Lilly and Novo Nordisk!
www.nejm.org/doi/full/10....
@rnflex.bsky.social
www.nejm.org/doi/full/10....
@rnflex.bsky.social
Exclusive: ProteinQure has raised an $11 million Series A, planning to enter the clinic later this year with its first drug candidate: a peptide-drug conjugate for triple-negative breast cancer
endpts.com/exclusive-pr...
endpts.com/exclusive-pr...
Exclusive: Toronto biotech ProteinQure nears the clinic with peptide platform as it raises $11M Series A
ProteinQure raises $11M Series A led by Heron Rock to advance PQ203, a peptide-drug conjugate for triple-negative breast cancer, into clinical trials by Q3, pivoting from quantum to AI.
endpts.com
May 27, 2025 at 12:29 PM
Exclusive: ProteinQure has raised an $11 million Series A, planning to enter the clinic later this year with its first drug candidate: a peptide-drug conjugate for triple-negative breast cancer
endpts.com/exclusive-pr...
endpts.com/exclusive-pr...
Great paper by the groups of Sylvestre Bonnet and Ewa Snaar-Jagalska in ACS Central Science. Ruthenium complexes with a caged integrin ligand have light-activated anti-cancer activity in 3D spheroids and in vivo as well as the ability to cross the BBB. #chemsky #ChemBio pubs.acs.org/doi/10.1021/...
Cyclic Ruthenium-Peptide Prodrugs Penetrate the Blood–Brain Barrier and Attack Glioblastoma upon Light Activation in Orthotopic Zebrafish Tumor Models
The blood–brain barrier (BBB) presents one of the main obstacles to delivering anticancer drugs in glioblastoma. Herein, we investigated the potential of a series of cyclic ruthenium-peptide conjugate...
pubs.acs.org
December 11, 2024 at 7:13 AM
Great paper by the groups of Sylvestre Bonnet and Ewa Snaar-Jagalska in ACS Central Science. Ruthenium complexes with a caged integrin ligand have light-activated anti-cancer activity in 3D spheroids and in vivo as well as the ability to cross the BBB. #chemsky #ChemBio pubs.acs.org/doi/10.1021/...
Presented at the #ADASciSessions:
The MariTide phase 2 trial of once-monthly maridebart cafraglutide, a peptide–antibody conjugate, showed substantial weight reduction in participants with obesity with or without type 2 diabetes. Full trial results: nej.md/3ZHxLeb
The MariTide phase 2 trial of once-monthly maridebart cafraglutide, a peptide–antibody conjugate, showed substantial weight reduction in participants with obesity with or without type 2 diabetes. Full trial results: nej.md/3ZHxLeb
June 23, 2025 at 6:35 PM
Presented at the #ADASciSessions:
The MariTide phase 2 trial of once-monthly maridebart cafraglutide, a peptide–antibody conjugate, showed substantial weight reduction in participants with obesity with or without type 2 diabetes. Full trial results: nej.md/3ZHxLeb
The MariTide phase 2 trial of once-monthly maridebart cafraglutide, a peptide–antibody conjugate, showed substantial weight reduction in participants with obesity with or without type 2 diabetes. Full trial results: nej.md/3ZHxLeb
NAR Cancer 5th anniversary symposium - fantastic first session today. Ranjit Bindra on development of innovative peptide-drug conjugate CBX-12 and Li Lan on RNA methyltransferase TRDMT1 as an emerging target. Recordings available for a limited time: fast.wistia.com/embed/channe...
January 9, 2025 at 8:55 PM
NAR Cancer 5th anniversary symposium - fantastic first session today. Ranjit Bindra on development of innovative peptide-drug conjugate CBX-12 and Li Lan on RNA methyltransferase TRDMT1 as an emerging target. Recordings available for a limited time: fast.wistia.com/embed/channe...
P2 data for the once monthly GIPR Antagonist GLP-1R agonist bispecific antibody, Maritide in people with #T2D as well as in #overweight and #obesity Even data for lower dose titration over several weeks in the same paper www.nejm.org/doi/full/10....
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial | NEJM
Maridebart cafraglutide (known as MariTide) is a long-acting peptide–antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide recep...
www.nejm.org
June 23, 2025 at 6:55 PM
P2 data for the once monthly GIPR Antagonist GLP-1R agonist bispecific antibody, Maritide in people with #T2D as well as in #overweight and #obesity Even data for lower dose titration over several weeks in the same paper www.nejm.org/doi/full/10....
Platt et al. Development and Evaluation of High Affinity Peptide-Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain
chemrxiv.org/engage/api-g...
chemrxiv.org/engage/api-g...
chemrxiv.org
July 5, 2025 at 6:50 AM
Platt et al. Development and Evaluation of High Affinity Peptide-Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain
chemrxiv.org/engage/api-g...
chemrxiv.org/engage/api-g...
The MariTide phase 2 trial of once-monthly maridebart cafraglutide, a peptide–antibody conjugate, showed substantial weight reduction in participants with #obesity with or without type 2 diabetes. Full trial results and Research Summary: nej.md/3ZHxLeb
#MedSky #EndoSky
#MedSky #EndoSky
September 6, 2025 at 4:01 PM
The MariTide phase 2 trial of once-monthly maridebart cafraglutide, a peptide–antibody conjugate, showed substantial weight reduction in participants with #obesity with or without type 2 diabetes. Full trial results and Research Summary: nej.md/3ZHxLeb
#MedSky #EndoSky
#MedSky #EndoSky
FIVE TARGETS. ONE MOLECULE. (It's a peptide-small molecule conjugate, so we're looking at 2+3=5 instead of one incredibly polypharmacological binding interface, but STILL.)
cen.acs.org/pharmaceutic...
cen.acs.org/pharmaceutic...
Not just GLP-1: Peptide-drug conjugate hits 5 obesity targets
Researchers combine pan-PPAR and dual-incretin receptor agonists for dramatic weight loss in mice
cen.acs.org
April 30, 2026 at 3:38 PM
FIVE TARGETS. ONE MOLECULE. (It's a peptide-small molecule conjugate, so we're looking at 2+3=5 instead of one incredibly polypharmacological binding interface, but STILL.)
cen.acs.org/pharmaceutic...
cen.acs.org/pharmaceutic...
Avacta's AVA6103 PDC hit preclinical PK predictions and showed clean safety across three dose levels in FOCUS-01. Early signals on a mechanism-of-action readout in solid tumours.
Avacta reports clinical proof of mechanism for AVA6103 PDC in FOCUS-01
Avacta's next-generation pre|CISION peptide-drug conjugate showed a clean safety profile and matched preclinical PK predictions across three dose levels in solid
biotech.disruptsmedia.com
September 30, 2026 at 6:00 PM
Avacta's AVA6103 PDC hit preclinical PK predictions and showed clean safety across three dose levels in FOCUS-01. Early signals on a mechanism-of-action readout in solid tumours.
We further showed that Alphafold could be used in a competition mode to identify peptides that bound nanobody with higher affinity than the wild type epitope peptide. We also used modeling to guide design of a peptide-electrophile conjugate that forms a crosslink with nanobody (3/n)
March 20, 2025 at 1:54 AM
We further showed that Alphafold could be used in a competition mode to identify peptides that bound nanobody with higher affinity than the wild type epitope peptide. We also used modeling to guide design of a peptide-electrophile conjugate that forms a crosslink with nanobody (3/n)
RESEARCH | 🧪
C Liu, M Véniant, @danieljdrucker.bsky.social et al
@amgen.bsky.social @sinaihealth.bsky.social
Part 1: This study and a co-pub delve into how both GIP receptor agonists and antagonists trigger weight loss through different mechanisms.
www.nature.com/articles/s42...
C Liu, M Véniant, @danieljdrucker.bsky.social et al
@amgen.bsky.social @sinaihealth.bsky.social
Part 1: This study and a co-pub delve into how both GIP receptor agonists and antagonists trigger weight loss through different mechanisms.
www.nature.com/articles/s42...
GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice - Nature Metabolism
This study, together with a companion manuscript, shows that in mice, weight loss as a result of GIP receptor antagonism requires and potentiates functional GLP-1 receptor signalling in the brain, exp...
www.nature.com
July 21, 2025 at 4:10 PM
RESEARCH | 🧪
C Liu, M Véniant, @danieljdrucker.bsky.social et al
@amgen.bsky.social @sinaihealth.bsky.social
Part 1: This study and a co-pub delve into how both GIP receptor agonists and antagonists trigger weight loss through different mechanisms.
www.nature.com/articles/s42...
C Liu, M Véniant, @danieljdrucker.bsky.social et al
@amgen.bsky.social @sinaihealth.bsky.social
Part 1: This study and a co-pub delve into how both GIP receptor agonists and antagonists trigger weight loss through different mechanisms.
www.nature.com/articles/s42...
Yeni bir 3'ü 1 arada antikor tümörleri hedef alıyor, ilaçları iletiyor ve bağışıklık hücrelerini aktive ederek daha güvenli kanser tedavisi vaat ediyor.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in...
Current applications of CD40-directed cancer immunotherapy rely on the release of endogenous tumor antigen for T cell priming and activation. Here the authors develop a bispecific CD40 agonistic antib...
www.nature.com
November 16, 2024 at 11:50 AM
Yeni bir 3'ü 1 arada antikor tümörleri hedef alıyor, ilaçları iletiyor ve bağışıklık hücrelerini aktive ederek daha güvenli kanser tedavisi vaat ediyor.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
🆕Once-Monthly💉 Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial | New England Journal of Medicine www.nejm.org/doi/full/10....
combines GLP-1 receptor agonism & glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism
#Nephrology #Nephsky #Nephbluesky #Medsky
combines GLP-1 receptor agonism & glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism
#Nephrology #Nephsky #Nephbluesky #Medsky
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial | NEJM
Maridebart cafraglutide (known as MariTide) is a long-acting peptide–antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide recep...
www.nejm.org
June 24, 2025 at 7:01 PM
🆕Once-Monthly💉 Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial | New England Journal of Medicine www.nejm.org/doi/full/10....
combines GLP-1 receptor agonism & glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism
#Nephrology #Nephsky #Nephbluesky #Medsky
combines GLP-1 receptor agonism & glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism
#Nephrology #Nephsky #Nephbluesky #Medsky
Very happy to share our latest work @acsnano
on applying #nanopore to protein analysis!
With the motor protein Hel308, we translocate DNA-peptide conjugate through MspA and successfully distinguish sulfation and phosphorylation at #singlemolecule level.
on applying #nanopore to protein analysis!
With the motor protein Hel308, we translocate DNA-peptide conjugate through MspA and successfully distinguish sulfation and phosphorylation at #singlemolecule level.
October 21, 2024 at 7:59 AM
Very happy to share our latest work @acsnano
on applying #nanopore to protein analysis!
With the motor protein Hel308, we translocate DNA-peptide conjugate through MspA and successfully distinguish sulfation and phosphorylation at #singlemolecule level.
on applying #nanopore to protein analysis!
With the motor protein Hel308, we translocate DNA-peptide conjugate through MspA and successfully distinguish sulfation and phosphorylation at #singlemolecule level.